RAINES MERILEE 4

What Happened Merilee Raines, a director of Ocular Therapeutix, was granted compensation awards on June 10, 2026: 14,000 restricted stock units (RSUs) and 44,000 derivative awards (options), each with an acquisition price of $0.00 (total reported value $0). These were reported on a Form 4 filed June 12, 2026. The awards are grants (not purchases or sales) and will vest only with continued service.

Key Details

• Transaction date: June 10, 2026; Form 4 filed June 12, 2026 (timely filing).
• Awards: 14,000 RSUs and 44,000 derivative awards (listed as granted; price reported $0.00).
• Vesting: Per footnotes, both awards vest 100% on the first anniversary of the grant date or, if earlier, immediately prior to the next annual meeting of stockholders, subject to continued board service.
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Footnotes: F1 describes the 14,000 RSUs (each RSU converts to one share). F2 describes the derivative awards as options with the same one-year vesting condition.
• No indication of a 10b5-1 plan, tax-withholding sale, or late filing in this report.

Context RSU grants and option awards to directors are routine elements of board compensation and do not by themselves signal insider buying or selling. RSUs entitle the holder to receive shares upon vesting; options give the holder the right to purchase shares later (subject to exercise and any strike price). Because these awards vest over time and were granted at $0.00, they reflect compensation rather than an immediate cash transaction or market bet.